Esperion Therapeutics ESPR Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's accrued manufacturing costs?
- Esperion Therapeutics (ESPR) reported accrued manufacturing costs of $6.94M in Q1 2026.
- How has Esperion Therapeutics's accrued manufacturing costs changed year-over-year?
- Esperion Therapeutics's accrued manufacturing costs increased by 8.1% year-over-year, from $6.42M to $6.94M.
- What is the long-term trend for Esperion Therapeutics's accrued manufacturing costs?
- Over 5 years (2020 to 2025), Esperion Therapeutics's accrued manufacturing costs has grown at a -4.7% compound annual growth rate (CAGR), from $15.16M to $11.94M.